Surrozen, Inc./DE

Consonance-HFW Acquisition Corp. (Nasdaq: CHFW) was a healthcare-focused special purpose acquisition company sponsored by Consonance Capital Management and HFW Capital that completed its initial public offering in 2021. The SPAC pursued targets in the biopharmaceutical and life sciences sectors, ultimately completing its business combination with Surrozen, Inc., a clinical-stage biotherapeutics company developing tissue-repair therapies through Wnt signaling pathway modulation. The May 2023 Form 8-K, filed under the Surrozen, Inc./DE registrant name, reflects post-merger reporting obligations of the combined entity following the de-SPAC transaction. Visit SpacDesk and sign up for full data on CHFW, including deal timelines, warrant terms, and comparable transactions across the healthcare SPAC universe.